Zhicheng Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhicheng Gong has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Kaisa Cui
Wuxi Cancer Institute Affiliated Hospital of Jiangnan University Wuxi Jiangsu China
2 shared publications - Liang Gong
Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Key Laboratory of Genome Manipulation and Biosynthesis, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
2 shared publications - Yan-Yan Chen
Cancer Institute, Institute of Integrated Chinese and Western Medicine, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
2 shared publications Aicun Li
The College of Basic Medical Science, Health Sciences Institute, China Medical University, Shenyang, Liaoning, China
1 shared publication- Ding-Qiao Xu
Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine, Xianyang 712046, China
1 shared publication Haocheng He
College of Synthetic Biology Industry, Center for Cell and Gene Therapy Research, Hunan University of Arts and Science, Changde, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 5 January 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (1) , 102537
5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation
- 5 January 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (1) , 102537
Top Cited PapersOpen Access5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation
- Open Access
- 1 January 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 3 (1) , 202619
Tumor but not tumor cells: Ferroptosis in non-tumor cells within the tumor
Ferroptosis is an iron-dependent form of regulated cell death that has attracted considerable attention as a promising therapeutic strategy because of its ability to eliminate tumor cells. However, tumors are multicellular ecosystems in which malignant cells coexist with diverse stromal and immune cell populations that critically shape tumor progression, anti-tumor immunity, and therapeutic responses. Emerging evidence indicates that ferroptosis exerts fundamentally distinct biological effects across these non-malignant cell populations, extending far beyond direct tumor cell killing. In this review, we propose a cell type-centered conceptual framework in which the consequences of ferroptosis are determined primarily by cellular context rather than by ferroptosis itself. While ferroptosis resistance enables certain cell types, such as fibroblasts and macrophages, within the tumor microenvironment (TME) to maintain tumor-promoting functions, ferroptosis compromises the persistence and effector activity of cytotoxic lymphocytes, including CD8+ T cells and natural killer cells. Conversely, ferroptosis in neutrophils and polymorphonuclear myeloid-derived suppressor cells may generate oxidized lipid mediators that paradoxically reinforce immune suppression despite reducing cell abundance. Therefore, in this review, we integrate recent advances in understanding ferroptosis across major nonmalignant cell populations within the TME, focusing on its effects on cell fate, functional plasticity, and anti-tumor immunity. We further discuss how these insights may guide the development of precision ferroptosis-based therapies that selectively target tumor-promoting cell states while preserving protective immune responses.
- 1 January 2026
- Published by Science Exploration Press in Ferroptosis and Oxidative Stress
- Vol. 3 (1) , 202619
Open AccessTumor but not tumor cells: Ferroptosis in non-tumor cells within the tumor
Ferroptosis is an iron-dependent form of regulated cell death that has attracted considerable attention as a promising therapeutic strategy because of its ability to eliminate tumor cells. However, tumors are multicellular ecosystems in which malignant cells coexist with diverse stromal and immune cell populations that critically shape tumor progression, anti-tumor immunity, and therapeutic responses. Emerging evidence indicates that ferroptosis exerts fundamentally distinct biological effects across these non-malignant cell populations, extending far beyond direct tumor cell killing. In this review, we propose a cell type-centered conceptual framework in which the consequences of ferroptosis are determined primarily by cellular context rather than by ferroptosis itself. While ferroptosis resistance enables certain cell types, such as fibroblasts and macrophages, within the tumor microenvironment (TME) to maintain tumor-promoting functions, ferroptosis compromises the persistence and effector activity of cytotoxic lymphocytes, including CD8+ T cells and natural killer cells. Conversely, ferroptosis in neutrophils and polymorphonuclear myeloid-derived suppressor cells may generate oxidized lipid mediators that paradoxically reinforce immune suppression despite reducing cell abundance. Therefore, in this review, we integrate recent advances in understanding ferroptosis across major nonmalignant cell populations within the TME, focusing on its effects on cell fate, functional plasticity, and anti-tumor immunity. We further discuss how these insights may guide the development of precision ferroptosis-based therapies that selectively target tumor-promoting cell states while preserving protective immune responses.
- 11 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 121032
Emerging insights into traditional Chinese medicine interventions for chemotherapy-induced cardiotoxicity
- 11 December 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 358, 121032
Emerging insights into traditional Chinese medicine interventions for chemotherapy-induced cardiotoxicity
- Open Access
- 25 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1) , 33
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis
Hepatocellular carcinoma (HCC) accounts for more than 90% of all liver cases and often responds poorly to conventional treatment modalities, including multi-kinase inhibitors and immune checkpoint inhibitors. Therefore, it is urgent to develop novel therapeutic options for HCC. In this study, we conducted high-throughput screening of histone demethylase inhibitors for HCC treatment. Among the inhibitors examined, Corin significantly suppressed the growth and proliferation of two HCC cell lines, HepG2 and Hep3B cells without affecting non-cancerous cells. Based on the targets of Corin, we identified HDAC1/KDM1A dual-positive HCC as a novel subtype of HCC. Transcriptome profiling indicated that this novel subtype possessed rapid proliferation and high DNA damage repair capacity. Additionally, Corin treatment upregulated FDX1 expression to trigger Cuproptosis, which suppressed HCC proliferation. Conclusively, Corin possesses potential application as a novel and effective therapeutic option for HCC that simultaneously inhibits KDM1A and HDAC1 expression.
- 25 November 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1) , 33
Open AccessCorin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis
Hepatocellular carcinoma (HCC) accounts for more than 90% of all liver cases and often responds poorly to conventional treatment modalities, including multi-kinase inhibitors and immune checkpoint inhibitors. Therefore, it is urgent to develop novel therapeutic options for HCC. In this study, we conducted high-throughput screening of histone demethylase inhibitors for HCC treatment. Among the inhibitors examined, Corin significantly suppressed the growth and proliferation of two HCC cell lines, HepG2 and Hep3B cells without affecting non-cancerous cells. Based on the targets of Corin, we identified HDAC1/KDM1A dual-positive HCC as a novel subtype of HCC. Transcriptome profiling indicated that this novel subtype possessed rapid proliferation and high DNA damage repair capacity. Additionally, Corin treatment upregulated FDX1 expression to trigger Cuproptosis, which suppressed HCC proliferation. Conclusively, Corin possesses potential application as a novel and effective therapeutic option for HCC that simultaneously inhibits KDM1A and HDAC1 expression.
- Open Access
- 12 September 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (39) , 3665-3678
FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy
The lack of a favorable tumor immune microenvironment (TIME) results in limited response rates to immune checkpoint blockade (ICB) across human solid tumors, necessitating the development of novel combination strategies. In this study, we repurposed FK228, an US FDA-approved histone deacetylase inhibitor that is used clinically in non-solid tumor treatment, as a novel ICB sensitizer in solid tumors and revealed the diverse regulatory functions of FK228 in the TIME. FK228 serves as a novel necroptosis inducer in cancer cells by triggering endoplasmic reticulum stress. This in turn enhances the immunogenicity of cancer cells and increases the infiltration of tumor-killing immunocytes, including CD8+ T and natural killer cells, particularly activating tumor-infiltrated CD8+ T cells. Meanwhile, FK228 treatment shifts macrophages toward the pro-inflammatory phenotype. Moreover, the combined use of FK228 and a PD-L1 inhibitor significantly delay tumor growth and extend the survival of tumor bearing mice. Overall, our findings reveal new possibilities for the clinical application of FK228 in solid tumors and underscore the critical role of histone deacetylases in maintaining the immune-unfavorable TIME.
- 12 September 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (39) , 3665-3678
Open AccessFK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy
The lack of a favorable tumor immune microenvironment (TIME) results in limited response rates to immune checkpoint blockade (ICB) across human solid tumors, necessitating the development of novel combination strategies. In this study, we repurposed FK228, an US FDA-approved histone deacetylase inhibitor that is used clinically in non-solid tumor treatment, as a novel ICB sensitizer in solid tumors and revealed the diverse regulatory functions of FK228 in the TIME. FK228 serves as a novel necroptosis inducer in cancer cells by triggering endoplasmic reticulum stress. This in turn enhances the immunogenicity of cancer cells and increases the infiltration of tumor-killing immunocytes, including CD8+ T and natural killer cells, particularly activating tumor-infiltrated CD8+ T cells. Meanwhile, FK228 treatment shifts macrophages toward the pro-inflammatory phenotype. Moreover, the combined use of FK228 and a PD-L1 inhibitor significantly delay tumor growth and extend the survival of tumor bearing mice. Overall, our findings reveal new possibilities for the clinical application of FK228 in solid tumors and underscore the critical role of histone deacetylases in maintaining the immune-unfavorable TIME.
- Open Access
- 12 May 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (10)
Emodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer
- 12 May 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (10)
Open AccessEmodin is a novel phosphatidylethanolamine anabolism inhibitor that reprograms lipid metabolism to overcome 5-fluorouracil resistance in colorectal cancer